Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Hilleman Labs Makeover Rides On New Technology For Heat-stable Rotavirus Vaccines

This article was originally published in PharmAsia News

Executive Summary

The vaccines research JV between Merck and Wellcome Trust has undergone major changes in its operations. The new plan is dramatically different from the one envisioned at the launch of the JV and narrows down on fewer disease areas with a predominant presence in enteric illnesses.

You may also be interested in...

Merck JV Ties Up With MEND To Focus On First Heat-stable Rotavirus Vaccine For Developing Markets

MUMBAI - Hilleman Laboratories - the nonprofit joint venture between Merck & Co. and Wellcome Trust to develop affordable vaccines for low-income countries - has set its sights on developing a heat-stable form of rotavirus vaccine as its first project

With More Vaccines For Low-Income Countries In Mind, Merck Signs JV With Wellcome Trust; India To Be Research And Manufacturing Hub

MUMBAI - New opportunities like preventive vaccines for developing countries are throwing up newer alliances between disparate stakeholders. In one such deal, New Jersey-headquartered Merck has formed a first-of-its-kind equal stake collaboration with Wellcome Trust of the United Kingdom to work on research and development of vaccines that can prevent diseases mainly in low-income countries

Indian Investors Turn Cautious On Compliance Concerns

A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts